All healthcare stakeholders are aware the day is coming when pharma manufacturers will need to go at-risk in order to secure inclusion of their high-cost drugs in plan formularies. This shouldn’t be viewed as simply a unilateral opportunity to force price concessions from manufacturers. Rather, this is an opportunity to place patient outcomes squarely in […]
We’ve talked about who we are: Curant Health is a team of healthcare experts who provide individualized, patient-centered services proven to deliver improved health outcomes. We’ve talked about what we bring to the healthcare table, including the improved outcomes we’ve demonstrated in HIV treatment and diabetes. Now it’s time to talk about ways we enjoy […]
As the creation of new drugs for chronic illness progresses, we ask ourselves certain questions when thinking from a biopharmaceutical manufacturer point of view: What key points do biopharmaceutical manufacturers consider when evaluating specialty pharmacy partners for distribution networks? What capabilities do they prioritize most highly? What factors benefit patients the most? Three metrics come […]
September 16, 2015 - Curant COO, Marc O'Connor, in Specialty Pharmacy Times - In the current landscape of specialty drugs for chronic care, including PCSK9 inhibitors topping $1,000 per month for life, what are the key factors biopharmaceutical manufacturers consider when evaluating specialty pharmacy partners for their distribution networks? We are always interested in learning […]
September 9, 2015 - Curant President and CEO, Patrick Dunham, in Managed Healthcare Executive - In the midst of the shift from fee-for-service to value based healthcare, pharmaceutical manufacturers continue churning out high-priced therapies. They may be justified to do so as long as the outcomes of the medication therapies outweigh the costs. We define “value” as […]
There’s an 80/20 rule when it comes to healthcare – 80% of healthcare cost comes from 20% of the populace, the chronically ill. According to the Deloitte Center for Health Solutions, healthcare spend in the United States is expected to eclipse $4 trillion this year. Take an estimated population of 319 million into consideration; that […]
August 30, 2015 - Curant COO, Marc O'Connor, in MedCity News - If it seems like every industry has some sort of 80-20 rule, that’s because it does. Entrepreneurs will tell you 80 percent of their profits come from 20 percent of their customers. Customer service reps will tell you they spend 80 percent of their time […]
For two days last month in Philadelphia, experts from pharmaceutical manufacturers, pharmacy benefit managers, and specialty pharmacists mingled in an open exchange of information and education at the 2nd Annual Summit on Specialty Distribution and Channel Optimization. There was a lot of talk around the intricacies of open, limited, and closed networks -- but since […]
August 12, 2015 – Atlanta, Georgia – Curant Health, an innovative medication management company, has been named on the Inc. 5000 list of fastest growing private companies in the U.S., having been the only large healthcare company to make the list for three consecutive years. This year Curant ranks #1004 on the prestigious list and is […]
August 13, 2015 - Curant Health COO, Marc O'Connor, in Managed Healthcare Executive - Out of $213 billion in avoidable annual healthcare costs, $105 billion is due to medication nonadherence, according to a recent IMS Health Informatics study. In addition to the potential cost savings associated with improved adherence, it could also lead to better […]
